Paclitaxel Treatment [T88.7]
OMIM number: 601129 (CYP2C8)
Dipl.-Biol. Birgit Busse
The enzyme CYP2C8 is majorly involved in the metabolism of the chemotherapeutic agent paclitaxel. Variants in the CYP2C8 gene can result in reduced enzyme activity.
The CYP2C8*3 allele leads to a reduction of enzyme activity up to 15% of the standard. Approximately 13% of all Caucasians are heterozygous, approximately 1.7% homozygous for the CYP2C8*3 allele. In both cases, toxicity may arise under the treatment with paclitaxel. Determining the CYP2C8 genotype prior to treatment provides the opportunity for dosage adaption of paclitaxel to prevent side-effects.